Stuart Poulton - 29 Jul 2025 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, Chief Development Officer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Stuart Poulton
Issuer symbol
KPTI
Transactions as of
29 Jul 2025
Net transactions value
-$835
Form type
4
Filing time
30 Jul 2025, 16:56:49 UTC
Previous filing
06 Mar 2025
Next filing
16 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Poulton Stuart EVP, Chief Development Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON /s/ Nancy Smith as Attorney-in-Fact for Stuart Poulton 30 Jul 2025 0001942597

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale $835 -191 -0.7% $4.37 27,223 29 Jul 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.